论文部分内容阅读
目的:探讨ehCGβ肿瘤基因疫苗诱生的效应脾细胞过继免疫在抗肿瘤中的作用。方法:通过转染建立稳定表达ehCGβ和HBV—preS2/S的细胞株Sp2/0-ehCGβ和Spz/0-preS2/S。以TR421-hCGβ质粒实施基因免疫,免疫后检测小鼠脾细胞,特异性细胞毒活性;同期将脾细胞过继免疫给正常小鼠,以过继TR421-hCGβ质粒免疫小鼠脾细胞为实验组、过继TR421质粒免疫小鼠脾细胞为对照组,检测脾细胞杀伤效应。结果:效应脾细胞对sp2/0-ehCGβ的杀伤率明显高于Sp2/0—preS2/S(P<0.05)。Sp2/0-ehCGβ在实验组小鼠仅2只形成实体瘤,TR421-hcGβ质粒基因免疫抗肿瘤任用有肿瘤特异性,两组有显著性差异(P<0.05),而在对照组小鼠均形成实体瘤。Sp2/0-preS2/S在所有的小鼠均形成了实体瘤,其瘤重无显著性差异。结论:ehCGβ肿瘤基因疫苗诱生的效应细胞可特异性杀伤肿瘤,过继免疫效应细胞能使正常小鼠获得明显的特异性抗肿瘤能力。
Objective: To investigate the role of ehCGβ tumor gene vaccine-induced adoptive immunity in spleen cells in anti-tumor effect. Methods: Sp2 / 0-ehCGβ and Spz / 0-preS2 / S cell lines stably expressing ehCGβ and HBV-preS2 / S were established by transfection. The TR421-hCGβ plasmid was used to perform gene immunization. After immunization, the splenocytes of mice were tested for their specific cytotoxicity. The splenocytes were adoptively immunized to normal mice at the same time, and the spleen cells were immunized with TR421-hCGβ plasmid as the experimental group. The spleen cells of TR421 plasmid-immunized mice served as the control group, and the spleen cell killing effect was detected. Results: The killing rate of sp2 / 0-ehCGβ was significantly higher than that of Sp2 / 0-preS2 / S (P <0.05). Only 2 of Sp2 / 0-ehCGβ mice formed solid tumors in the experimental group, and TR421-hcGβ plasmid had antitumor activity on a tumor-specific basis. There was a significant difference between the two groups (P <0.05) The formation of solid tumors. Sp2 / 0-preS2 / S formed solid tumors in all mice with no significant difference in tumor weight. CONCLUSION: The effector cells induced by ehCGβ tumor gene vaccine can specifically kill the tumor. Adoptive immune effector cells can make the normal mice acquire obvious specific anti-tumor ability.